|
121 Companies |
|
195 Products |
|
195 Products |
|
116 Mechanisms of Action |
|
3 Trials |
|
2334 News |
|
| «12...2122232425262728293031...4647» |
- Apidra (insulin glulisine) / Sanofi
Trial completion, Trial primary completion date: Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients. (clinicaltrials.gov) - Jun 17, 2014
P2, N=12, Completed, Sponsor: HealthPartners Institute for Education and Research
Active, not recruiting --> Completed | Trial primary completion date: Mar 2013 --> Jun 2013
- |||| vanutide cridificar (PF-236806) / J&J, Perrigo Company, Pfizer
Trial completion: Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease (clinicaltrials.gov) - Jun 17, 2014
P2, N=63, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed | Trial primary completion date: Mar 2013 --> Jun 2013 Recruiting --> Completed
- Trial primary completion date: Maximizing Independence at Home (MIND at Home) (clinicaltrials.gov) - Jun 13, 2014
P2/3, N=303, Completed, Sponsor: Johns Hopkins University
Recruiting --> Completed Trial primary completion date: May 2010 --> Dec 2011
- ||| donepezil / Generic mfg.
Clinical: Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice (clinicaltrials.gov) - Jun 13, 2014
P=N/A, N=10000, Recruiting, Sponsor: Eisai Co., Ltd.
- ||| memantine / Generic mfg.
Combination therapy: Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease (clinicaltrials.gov) - Jun 13, 2014
P=N/A, N=5000, Recruiting, Sponsor: Eisai Co., Ltd.
- | Trial completion: Maximizing Independence at Home (MIND at Home) (clinicaltrials.gov) - Jun 13, 2014
P2/3, N=303, Completed, Sponsor: Johns Hopkins University
Trial primary completion date: May 2010 --> Dec 2011 Active, not recruiting --> Completed
- | Phase classification: A Study on Behavioral and Psychological Symptoms of Dementia (clinicaltrials.gov) - Jun 12, 2014
P4, N=359, Completed, Sponsor: Johnson & Johnson Taiwan Ltd
Active, not recruiting --> Completed Phase classification: P=N/A --> P4
- | galantamine hydrobromide / Generic mfg.
Clinical data, Phase classification: An Observational Study of the Safety and Effectiveness of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-month Period (clinicaltrials.gov) - Jun 12, 2014
P4, N=61, Completed, Sponsor: Janssen-Cilag Pty Ltd
Phase classification: P=N/A --> P4 Phase classification: P=N/A --> P4
- haloperidol / Generic mfg.
Trial primary completion date: HARPOON: Haloperidol Prophylaxis in Older Emergency Department Patients (clinicaltrials.gov) - Jun 12, 2014
P4, N=780, Recruiting, Sponsor: VU University Medical Center
Phase classification: P=N/A --> P4 Trial primary completion date: Apr 2014 --> May 2015
- haloperidol / Generic mfg.
Enrollment change: HARPOON: Haloperidol Prophylaxis in Older Emergency Department Patients (clinicaltrials.gov) - Jun 12, 2014
P4, N=780, Recruiting, Sponsor: VU University Medical Center
Trial primary completion date: Apr 2014 --> May 2015 N=600 --> 780
- Enrollment closed: SensiCare: Sensory Support Care for Elderly Patients Suffering From Alzheimer'S-type Neurodegenerative Disease (clinicaltrials.gov) - Jun 12, 2014
P=N/A, N=31, Active, not recruiting, Sponsor: Centre Hospitalier Universitaire de Nīmes
N=600 --> 780 Recruiting --> Active, not recruiting
- ||| donepezil / Generic mfg.
Clinical: A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients (clinicaltrials.gov) - Jun 4, 2014
P=N/A, N=6660, Recruiting, Sponsor: Eisai Korea Inc.
- ||| donepezil / Generic mfg.
Enrollment open: A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients (clinicaltrials.gov) - Jun 4, 2014
P=N/A, N=6660, Recruiting, Sponsor: Eisai Korea Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- GSK2647544 / GSK
Trial termination: GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers (clinicaltrials.gov) - Jun 4, 2014
P1, N=12, Terminated, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Recruiting --> Terminated; Given the strength of CYP3A4 inhibition observed in Cohort 1, there is no rationale to investigate higher doses of GSK2647544 in the following two cohorts
- rilapladib (SB-659032) / GSK
Trial primary completion date: Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers (clinicaltrials.gov) - Jun 4, 2014
P1, N=30, Not yet recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Terminated; Given the strength of CYP3A4 inhibition observed in Cohort 1, there is no rationale to investigate higher doses of GSK2647544 in the following two cohorts Trial primary completion date: Aug 2014 --> Sep 2014
- rilapladib (SB-659032) / GSK
Trial initiation date: Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers (clinicaltrials.gov) - Jun 4, 2014
P1, N=30, Not yet recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Aug 2014 --> Sep 2014 Initiation date: May 2014 --> Jun 2014
- GSK2647544 / GSK
Enrollment change: GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers (clinicaltrials.gov) - Jun 4, 2014
P1, N=48, Recruiting, Sponsor: GlaxoSmithKline
Initiation date: May 2014 --> Jun 2014 N=70 --> 48
- Trial primary completion date: Cataract Removal and Alzheimer's Disease (clinicaltrials.gov) - Jun 2, 2014
P=N/A, N=210, Recruiting, Sponsor: University Hospital Case Medical Center
N=70 --> 48 Trial primary completion date: Dec 2013 --> Jun 2015
- Clinical: DanceFit;DanceFit Prime: DanceFit Prime: A Dance Based Physical Activity and Nutritional Intervention for Primary Care - A Feasibility Study (clinicaltrials.gov) - Jun 2, 2014
P=N/A, N=40, Not yet recruiting, Sponsor: North Essex Partnership NHS Foundation Trust
- Trial primary completion date: Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls (clinicaltrials.gov) - Jun 1, 2014
P1, N=4, Completed, Sponsor: Institute for Neurodegenerative Disorders
Trial primary completion date: Dec 2013 --> Jun 2015 Trial primary completion date: Aug 2014 --> Sep 2012
- Enrollment change: Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls (clinicaltrials.gov) - Jun 1, 2014
P1, N=4, Completed, Sponsor: Institute for Neurodegenerative Disorders
Trial primary completion date: Aug 2014 --> Sep 2012 N=32 --> 4
- Trial completion: Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls (clinicaltrials.gov) - Jun 1, 2014
P1, N=4, Completed, Sponsor: Institute for Neurodegenerative Disorders
N=32 --> 4 Active, not recruiting --> Completed
- Enrollment open: Massage Technique for Pain, Anxiety and Delirium in SAH Patients (clinicaltrials.gov) - May 31, 2014
P=N/A, N=50, Recruiting, Sponsor: Sara E. Hocker, M.D
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial primary completion date: Two Interventions for Early Stage Dementia: A Comparative Efficacy Trial (clinicaltrials.gov) - May 28, 2014
P=N/A, N=240, Recruiting, Sponsor: University of Washington
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2013 --> Dec 2014
- Enrollment change, HEOR: Phase II Early Behavioral Intervention in BMT w/ Sleep Disturbance-Assess QOL+Fatigue+Cognitive f(x) (clinicaltrials.gov) - May 28, 2014
P2, N=29, Completed, Sponsor: Stanford University
Trial primary completion date: Dec 2013 --> Dec 2014 N=50 --> 29
- Trial completion, HEOR: Phase II Early Behavioral Intervention in BMT w/ Sleep Disturbance-Assess QOL+Fatigue+Cognitive f(x) (clinicaltrials.gov) - May 28, 2014
P2, N=29, Completed, Sponsor: Stanford University
N=50 --> 29 Recruiting --> Completed
- Trial primary completion date: Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects. (clinicaltrials.gov) - May 28, 2014
P1, N=80, Recruiting, Sponsor: Institute for Neurodegenerative Disorders
Recruiting --> Completed Trial primary completion date: Aug 2014 --> May 2015
- Trial completion date: Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects. (clinicaltrials.gov) - May 28, 2014
P1, N=80, Recruiting, Sponsor: Institute for Neurodegenerative Disorders
Trial primary completion date: Aug 2014 --> May 2015 Trial completion date: Aug 2014 --> May 2015
- Trial primary completion date: Effects of a Combined Transcranial Magnetic Stimulation (TMS) and Cognitive Training in Alzheimer Patients (clinicaltrials.gov) - May 27, 2014
P2, N=20, Active, not recruiting, Sponsor: Beth Israel Deaconess Medical Center
Trial completion date: Aug 2014 --> May 2015 Trial primary completion date: Mar 2014 --> Oct 2014
- Trial primary completion date: Insulin Resistance and Cognitive Dysfunction in Obese Adolescents: Pilot Study (clinicaltrials.gov) - May 26, 2014
P=N/A, N=50, Recruiting, Sponsor: Winthrop University Hospital
Trial primary completion date: Mar 2014 --> Oct 2014 Trial primary completion date: Jan 2014 --> Jan 2015
- Trial primary completion date: Direct Noise Reduction in the Intensive Care Units (ICU) Using Earplugs and Noise Canceling Headphones (clinicaltrials.gov) - May 26, 2014
P2/3, N=45, Suspended, Sponsor: Wake Forest School of Medicine
Trial primary completion date: Jan 2014 --> Jan 2015 Trial primary completion date: Dec 2011 --> Dec 2014
- Trial suspension: Direct Noise Reduction in the Intensive Care Units (ICU) Using Earplugs and Noise Canceling Headphones (clinicaltrials.gov) - May 26, 2014
P2/3, N=45, Suspended, Sponsor: Wake Forest School of Medicine
Trial primary completion date: Dec 2011 --> Dec 2014 Recruiting --> Suspended
- Trial completion date: Direct Noise Reduction in the Intensive Care Units (ICU) Using Earplugs and Noise Canceling Headphones (clinicaltrials.gov) - May 26, 2014
P2/3, N=45, Suspended, Sponsor: Wake Forest School of Medicine
Recruiting --> Suspended Trial completion date: Jun 2012 --> Jun 2015
- Daytrana (methylphenidate transdermal system) / Hisamitsu
Trial primary completion date: Exploring the Use of Transdermal Methylphenidate to Reduce Fall Risk in Patients With Dementia. (clinicaltrials.gov) - May 21, 2014
P4, N=40, Enrolling by invitation, Sponsor: St. Louis University
Trial completion date: Jun 2012 --> Jun 2015 Trial primary completion date: Dec 2013 --> Dec 2014
- Trial primary completion date: CONFUCIUS: Impact of a Multifaceted Program to Prevent Postoperative Delirium in the Elderly (clinicaltrials.gov) - May 21, 2014
P=N/A, N=360, Recruiting, Sponsor: Hospices Civils de Lyon
Trial primary completion date: Dec 2013 --> Dec 2014 Trial primary completion date: Sep 2015 --> Apr 2016
- Trial initiation date: CONFUCIUS: Impact of a Multifaceted Program to Prevent Postoperative Delirium in the Elderly (clinicaltrials.gov) - May 21, 2014
P=N/A, N=360, Recruiting, Sponsor: Hospices Civils de Lyon
Trial primary completion date: Sep 2015 --> Apr 2016 Initiation date: Mar 2011 --> Apr 2011
- ||| galantamine hydrobromide / Generic mfg.
Clinical data, Trial initiation date: An Observational Study of the Safety and Effectiveness of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-month Period (clinicaltrials.gov) - May 21, 2014
P4, N=61, Completed, Sponsor: Janssen-Cilag Pty Ltd
Initiation date: Mar 2011 --> Apr 2011 Initiation date: Apr 2005 --> May 2005
- Daytrana (methylphenidate transdermal system) / Hisamitsu
Trial completion date: Exploring the Use of Transdermal Methylphenidate to Reduce Fall Risk in Patients With Dementia. (clinicaltrials.gov) - May 21, 2014
P4, N=40, Enrolling by invitation, Sponsor: St. Louis University
Initiation date: Apr 2005 --> May 2005 Trial completion date: Feb 2014 --> Dec 2014
- Trial completion date: CONFUCIUS: Impact of a Multifaceted Program to Prevent Postoperative Delirium in the Elderly (clinicaltrials.gov) - May 21, 2014
P=N/A, N=360, Recruiting, Sponsor: Hospices Civils de Lyon
Trial completion date: Feb 2014 --> Dec 2014 Trial completion date: Sep 2015 --> Apr 2016
- || dexmedetomidine / Generic mfg.
Surgery: Reducing Delirium After Cardiac Surgery: A Multifaceted Approach Of Perioperative Care (clinicaltrials.gov) - May 20, 2014
P=N/A, N=200, Recruiting, Sponsor: University Health Network, Toronto
Trial completion date: Sep 2015 --> Apr 2016 Trial primary completion date: Dec 2013 --> Sep 2014
- | dexmedetomidine / Generic mfg.
Surgery: Reducing Delirium After Cardiac Surgery: A Multifaceted Approach Of Perioperative Care (clinicaltrials.gov) - May 20, 2014
P=N/A, N=200, Recruiting, Sponsor: University Health Network, Toronto
Trial primary completion date: Dec 2013 --> Sep 2014 Trial completion date: Dec 2013 --> Dec 2014
- ||||||| rivastigmine transdermal / Generic mfg.
Trial completion: Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20) (clinicaltrials.gov) - May 20, 2014
P3, N=101, Completed, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2013 --> Dec 2014 Active, not recruiting --> Completed
- Trial primary completion date, Surgery: Role of Cerebral Oximetry In Reducing Delirium After Complex Cardiac Surgery (clinicaltrials.gov) - May 20, 2014
P=N/A, N=266, Recruiting, Sponsor: University Health Network, Toronto
Active, not recruiting --> Completed Trial primary completion date: Mar 2014 --> Sep 2014
- Trial completion date, Surgery: Role of Cerebral Oximetry In Reducing Delirium After Complex Cardiac Surgery (clinicaltrials.gov) - May 20, 2014
P=N/A, N=266, Recruiting, Sponsor: University Health Network, Toronto
Trial primary completion date: Mar 2014 --> Sep 2014 Trial completion date: Jul 2014 --> Dec 2014
- || rivastigmine transdermal / Generic mfg., rivastigmine / Generic mfg.
Trial primary completion date: Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia (clinicaltrials.gov) - May 20, 2014
P4, N=127, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Jul 2014 --> Dec 2014 Trial primary completion date: Dec 2014 --> Apr 2015
- || rivastigmine transdermal / Generic mfg., rivastigmine / Generic mfg.
Trial completion date: Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia (clinicaltrials.gov) - May 20, 2014
P4, N=127, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2014 --> Apr 2015 Trial completion date: Dec 2014 --> Apr 2015
- Trial initiation date: A Family Intervention for Delirium Prevention (clinicaltrials.gov) - May 19, 2014
P=N/A, N=80, Recruiting, Sponsor: Lawson Health Research Institute
Trial completion date: Dec 2014 --> Apr 2015 Initiation date: Apr 2014 --> Mar 2014
- Enrollment open: A Family Intervention for Delirium Prevention (clinicaltrials.gov) - May 19, 2014
P=N/A, N=80, Recruiting, Sponsor: Lawson Health Research Institute
Initiation date: Apr 2014 --> Mar 2014 Not yet recruiting --> Recruiting
- Biomarker: Down Syndrome Biomarker Initiative (DSBI) (clinicaltrials.gov) - May 18, 2014
P=N/A, N=12, Active, not recruiting, Sponsor: Alzheimer's Disease Cooperative Study (ADCS)
- New P1/2 trial: Phase 1 and Phase 2 Clinical Trials of SNUBH-NM-333(18F) (clinicaltrials.gov) - May 18, 2014
P1/2, N=30, Terminated, Sponsor: Seoul National University Hospital